Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2017

01-01-2017 | Epidemiology

A model for individualized risk prediction of contralateral breast cancer

Authors: Marzana Chowdhury, David Euhus, Tracy Onega, Swati Biswas, Pankaj K. Choudhary

Published in: Breast Cancer Research and Treatment | Issue 1/2017

Login to get access

Abstract

Purpose

Patients diagnosed with invasive breast cancer (BC) or ductal carcinoma in situ are increasingly choosing to undergo contralateral prophylactic mastectomy (CPM) to reduce their risk of contralateral BC (CBC). This is a particularly disturbing trend as a large proportion of these CPMs are believed to be medically unnecessary. Many BC patients tend to substantially overestimate their CBC risk. Thus, there is a pressing need to educate patients effectively on their CBC risk. We develop a CBC risk prediction model to aid physicians in this task.

Methods

We used data from two sources: Breast Cancer Surveillance Consortium and Surveillance, Epidemiology, and End Results to build the model. The model building steps are similar to those used in developing the BC risk assessment tool (popularly known as Gail model) for counseling women on their BC risk. Our model, named CBCRisk, is exclusively designed for counseling women diagnosed with unilateral BC on the risk of developing CBC.

Results

We identified eight factors to be significantly associated with CBC—age at first BC diagnosis, anti-estrogen therapy, family history of BC, high-risk pre-neoplasia status, estrogen receptor status, breast density, type of first BC, and age at first birth. Combining the relative risk estimates with the relevant hazard rates, CBCRisk projects absolute risk of developing CBC over a given period.

Conclusions

By providing individualized CBC risk estimates, CBCRisk may help in counseling of BC patients. In turn, this may potentially help alleviate the rate of medically unnecessary CPMs.
Appendix
Available only for authorised users
Literature
1.
go back to reference Tuttle TM, Habermann EB, Grund EH et al (2007) Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 25:5203–5209CrossRefPubMed Tuttle TM, Habermann EB, Grund EH et al (2007) Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 25:5203–5209CrossRefPubMed
2.
go back to reference Tuttle TM, Jarosek S, Habermann EB et al (2009) Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol 27:1362–1367CrossRefPubMed Tuttle TM, Jarosek S, Habermann EB et al (2009) Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol 27:1362–1367CrossRefPubMed
3.
go back to reference King TA, Sakr R, Patil S et al (2011) Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol 29:2158–2164CrossRefPubMed King TA, Sakr R, Patil S et al (2011) Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol 29:2158–2164CrossRefPubMed
4.
go back to reference Yao K, Stewart AK, Winchester DJ, Winchester DP (2010) Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Data Base, 1998–2007. Ann Surg Oncol 17:2554–2562CrossRefPubMed Yao K, Stewart AK, Winchester DJ, Winchester DP (2010) Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Data Base, 1998–2007. Ann Surg Oncol 17:2554–2562CrossRefPubMed
5.
go back to reference Katipamula R, Degnim AC, Hoskin T et al (2009) Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol 27:4082–4088CrossRefPubMedPubMedCentral Katipamula R, Degnim AC, Hoskin T et al (2009) Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol 27:4082–4088CrossRefPubMedPubMedCentral
6.
go back to reference Wong SM, Freedman RA, Sagara Y et al (2016) Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer. Ann Surg. doi:10.1097/SLA.0000000000001698 Wong SM, Freedman RA, Sagara Y et al (2016) Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer. Ann Surg. doi:10.​1097/​SLA.​0000000000001698​
7.
go back to reference Nichols HB, Berrington de Gonzalez A, Lacey JV et al (2011) Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol 29:1564–1569CrossRefPubMedPubMedCentral Nichols HB, Berrington de Gonzalez A, Lacey JV et al (2011) Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol 29:1564–1569CrossRefPubMedPubMedCentral
8.
go back to reference Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45–53CrossRef Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45–53CrossRef
9.
go back to reference Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef
10.
go back to reference Cuzick J, Sestak I, Baum M et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135–1141CrossRefPubMed Cuzick J, Sestak I, Baum M et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135–1141CrossRefPubMed
11.
go back to reference Uyeno L, Behrendt, Vito C (2012) Contralateral breast cancer: impact on survival after unilateral breast cancer is stage-dependent. In: ASCO breast cancer symposium abstract 69 Uyeno L, Behrendt, Vito C (2012) Contralateral breast cancer: impact on survival after unilateral breast cancer is stage-dependent. In: ASCO breast cancer symposium abstract 69
12.
go back to reference Bertelsen L, Bernstein L, Olsen JH et al (2008) Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women’s Environment, Cancer and Radiation Epidemiology Study. J Natl Cancer Inst 100:32–40CrossRefPubMed Bertelsen L, Bernstein L, Olsen JH et al (2008) Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women’s Environment, Cancer and Radiation Epidemiology Study. J Natl Cancer Inst 100:32–40CrossRefPubMed
13.
go back to reference Kurian AW, McClure LA, John EM et al (2009) Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst 101:1058–1065CrossRefPubMedPubMedCentral Kurian AW, McClure LA, John EM et al (2009) Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst 101:1058–1065CrossRefPubMedPubMedCentral
14.
go back to reference Brewster AM, Parker PA (2011) Current knowledge on contralateral prophylactic mastectomy among women with sporadic breast cancer. Oncologist 16:935–941CrossRefPubMedPubMedCentral Brewster AM, Parker PA (2011) Current knowledge on contralateral prophylactic mastectomy among women with sporadic breast cancer. Oncologist 16:935–941CrossRefPubMedPubMedCentral
15.
go back to reference Bouchardy C, Benhamou S, Fioretta G et al (2011) Risk of second breast cancer according to estrogen receptor status and family history. Breast Cancer Res Treat 127:233–241CrossRefPubMed Bouchardy C, Benhamou S, Fioretta G et al (2011) Risk of second breast cancer according to estrogen receptor status and family history. Breast Cancer Res Treat 127:233–241CrossRefPubMed
16.
go back to reference Khan SA (2011) Contralateral prophylactic mastectomy: What do we know and what do our patients know? J Clin Oncol 29:2132–2135CrossRefPubMed Khan SA (2011) Contralateral prophylactic mastectomy: What do we know and what do our patients know? J Clin Oncol 29:2132–2135CrossRefPubMed
17.
go back to reference Murphy JA, Milner TD, O’Donoghue JM (2013) Contralateral risk-reducing mastectomy in sporadic breast cancer. Lancet Oncol 14:e262–e269CrossRefPubMed Murphy JA, Milner TD, O’Donoghue JM (2013) Contralateral risk-reducing mastectomy in sporadic breast cancer. Lancet Oncol 14:e262–e269CrossRefPubMed
18.
go back to reference Chen Y, Thompson W, Semenciw R, Mao Y (1999) Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomark Prev 8:855–861 Chen Y, Thompson W, Semenciw R, Mao Y (1999) Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomark Prev 8:855–861
19.
go back to reference Graeser MK, Engel C, Rhiem K et al (2009) Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 27:5887–5892CrossRefPubMed Graeser MK, Engel C, Rhiem K et al (2009) Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 27:5887–5892CrossRefPubMed
20.
go back to reference Cook LS, White E, Schwartz SM et al (1996) A population-based study of contralateral breast cancer following a first primary breast cancer (Washington, United States). Cancer Causes Control 7:382–390CrossRefPubMed Cook LS, White E, Schwartz SM et al (1996) A population-based study of contralateral breast cancer following a first primary breast cancer (Washington, United States). Cancer Causes Control 7:382–390CrossRefPubMed
21.
go back to reference Haffty BG, Harrold E, Khan AJ et al (2002) Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 359:1471–1477CrossRefPubMed Haffty BG, Harrold E, Khan AJ et al (2002) Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 359:1471–1477CrossRefPubMed
22.
go back to reference Rhiem K, Engel C, Graeser M et al (2012) The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res 14:R156CrossRefPubMedPubMedCentral Rhiem K, Engel C, Graeser M et al (2012) The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res 14:R156CrossRefPubMedPubMedCentral
23.
go back to reference Reiner AS, John EM, Brooks JD et al (2013) Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women’s Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol 31:433–439CrossRefPubMed Reiner AS, John EM, Brooks JD et al (2013) Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women’s Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol 31:433–439CrossRefPubMed
25.
go back to reference Schaapveld M, Visser O, Louwman WJ et al (2008) The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat 110:189–197CrossRefPubMed Schaapveld M, Visser O, Louwman WJ et al (2008) The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat 110:189–197CrossRefPubMed
26.
go back to reference Saltzman BS, Malone KE, McDougall JA et al (2012) Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer. Breast Cancer Res Treat 135:849–855CrossRefPubMedPubMedCentral Saltzman BS, Malone KE, McDougall JA et al (2012) Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer. Breast Cancer Res Treat 135:849–855CrossRefPubMedPubMedCentral
27.
go back to reference Cook LS, Weiss NS, Schwartz SM et al (1995) Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst 87:1359–1364CrossRefPubMed Cook LS, Weiss NS, Schwartz SM et al (1995) Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst 87:1359–1364CrossRefPubMed
28.
go back to reference Herrinton LJ, Barlow WE, Yu O et al (2005) Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol 23:4275–4286CrossRefPubMed Herrinton LJ, Barlow WE, Yu O et al (2005) Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol 23:4275–4286CrossRefPubMed
29.
go back to reference Abbott A, Rueth N, Pappas-Varco S et al (2011) Perceptions of contralateral breast cancer: an overestimation of risk. Ann Surg Oncol 18:3129–3136CrossRefPubMed Abbott A, Rueth N, Pappas-Varco S et al (2011) Perceptions of contralateral breast cancer: an overestimation of risk. Ann Surg Oncol 18:3129–3136CrossRefPubMed
30.
go back to reference Metcalfe KA, Narod SA (2002) Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy. J Natl Cancer Inst 94:1564–1569CrossRefPubMed Metcalfe KA, Narod SA (2002) Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy. J Natl Cancer Inst 94:1564–1569CrossRefPubMed
31.
go back to reference Lostumbo L, Carbine N, Wallace J, Ezzo J (2004) Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev (4):CD002748 Lostumbo L, Carbine N, Wallace J, Ezzo J (2004) Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev (4):CD002748
32.
go back to reference Lostumbo L, Carbine NE, Wallace J (2010) Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev (11):CD002748 Lostumbo L, Carbine NE, Wallace J (2010) Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev (11):CD002748
33.
go back to reference Boughey JC, Hoskin TL, Degnim AC et al (2010) Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol 17:2702–2709CrossRefPubMedPubMedCentral Boughey JC, Hoskin TL, Degnim AC et al (2010) Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol 17:2702–2709CrossRefPubMedPubMedCentral
34.
go back to reference Carson W, Otteson R, Hughes MA et al (2013) Contralateral prophylactic mastectomy for unilateral breast cancer: a review of the National Comprehensive Cancer Network (NCCN) database. In: Society of Surgical Oncology 66th annual cancer symposium abstract 13 Carson W, Otteson R, Hughes MA et al (2013) Contralateral prophylactic mastectomy for unilateral breast cancer: a review of the National Comprehensive Cancer Network (NCCN) database. In: Society of Surgical Oncology 66th annual cancer symposium abstract 13
35.
go back to reference Frost MH, Schaid DJ, Sellers TA et al (2000) Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA 284:319–324CrossRefPubMed Frost MH, Schaid DJ, Sellers TA et al (2000) Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA 284:319–324CrossRefPubMed
36.
37.
go back to reference Payne DK, Biggs C, Tran KN et al (2000) Women’s regrets after bilateral prophylactic mastectomy. Ann Surg Oncol 7:150–154CrossRefPubMed Payne DK, Biggs C, Tran KN et al (2000) Women’s regrets after bilateral prophylactic mastectomy. Ann Surg Oncol 7:150–154CrossRefPubMed
38.
go back to reference Gartner R, Jensen MB, Nielsen J et al (2009) Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA 302:1985–1992CrossRefPubMed Gartner R, Jensen MB, Nielsen J et al (2009) Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA 302:1985–1992CrossRefPubMed
39.
go back to reference Gahm J, Wickman M, Brandberg Y (2010) Bilateral prophylactic mastectomy in women with inherited risk of breast cancer—prevalence of pain and discomfort, impact on sexuality, quality of life and feelings of regret two years after surgery. Breast 19:462–469CrossRefPubMed Gahm J, Wickman M, Brandberg Y (2010) Bilateral prophylactic mastectomy in women with inherited risk of breast cancer—prevalence of pain and discomfort, impact on sexuality, quality of life and feelings of regret two years after surgery. Breast 19:462–469CrossRefPubMed
40.
go back to reference Gail MH, Brinton LA, Byar DP et al (1989) Projecting individualized probabilities of developing breast cancer for White females who are being examined annually. J Natl Cancer Inst 81:1879–1886CrossRefPubMed Gail MH, Brinton LA, Byar DP et al (1989) Projecting individualized probabilities of developing breast cancer for White females who are being examined annually. J Natl Cancer Inst 81:1879–1886CrossRefPubMed
42.
go back to reference Surveillance, Epidemiology, and End Results (SEER) program: research data (1973–2010). National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch. www.seer.cancer.gov. Accessed 31 May 2016 Surveillance, Epidemiology, and End Results (SEER) program: research data (1973–2010). National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch. www.​seer.​cancer.​gov. Accessed 31 May 2016
43.
go back to reference Ballard-Barbash R, Taplin SH, Yankaskas BC et al (1997) Breast Cancer Surveillance Consortium: a national mammography screening and outcomes database. Am J Roentgenol 169:1001–1008CrossRef Ballard-Barbash R, Taplin SH, Yankaskas BC et al (1997) Breast Cancer Surveillance Consortium: a national mammography screening and outcomes database. Am J Roentgenol 169:1001–1008CrossRef
44.
go back to reference Hosmer DW, Lemeshow S (2000) Applied logistic regression, 2nd edn. Wiley, New YorkCrossRef Hosmer DW, Lemeshow S (2000) Applied logistic regression, 2nd edn. Wiley, New YorkCrossRef
46.
go back to reference Houssami N, Abraham LA, Kerlikowske K et al (2013) Risk factors for second screen-detected or interval breast cancers in women with a personal history of breast cancer participating in mammography screening. Cancer Epidemiol Biomark Prev 22:946–961CrossRef Houssami N, Abraham LA, Kerlikowske K et al (2013) Risk factors for second screen-detected or interval breast cancers in women with a personal history of breast cancer participating in mammography screening. Cancer Epidemiol Biomark Prev 22:946–961CrossRef
47.
go back to reference Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145–158CrossRefPubMedPubMedCentral Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145–158CrossRefPubMedPubMedCentral
48.
go back to reference Biswas S, Atienza P, Chipman J et al (2013) Simplifying clinical use of the genetic risk prediction model BRCAPRO. Breast Cancer Res Treat 139:571–579CrossRefPubMedPubMedCentral Biswas S, Atienza P, Chipman J et al (2013) Simplifying clinical use of the genetic risk prediction model BRCAPRO. Breast Cancer Res Treat 139:571–579CrossRefPubMedPubMedCentral
Metadata
Title
A model for individualized risk prediction of contralateral breast cancer
Authors
Marzana Chowdhury
David Euhus
Tracy Onega
Swati Biswas
Pankaj K. Choudhary
Publication date
01-01-2017
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-4039-x

Other articles of this Issue 1/2017

Breast Cancer Research and Treatment 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine